Recent Study from England’s National Health Service Highlights Positive Impact of Implementing HeartFlow’s FFRCT Analysis for Diagnosis of Coronary Artery Disease

Excerpt from the Press Release:

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Two-year results from FISH&CHIPS, a real world, multi-center, retrospective clinical study with 90,553 patients conducted by the National Health Service (NHS) England were presented at the 2023 European Society of Cardiology (ESC) Congress meeting in Amsterdam by Principal Investigator, Dr. Tim Fairbairn, Consultant Cardiologist, Liverpool Heart and Chest Hospital.

FFR_CT (CCTA-derived Fractional Flow Reserve) is part of a clinical pathway for evaluation and diagnosis of coronary artery disease (CAD) that provides clear insight into a patient’s condition with a patient-specific visual model of the heart’s blood flow, helping physicians make more accurate diagnoses and treatment decisions.

The FISH&CHIPS study was designed to assess at a national level the incremental impact of adding HeartFlow FFR_CT to a CCTA-first (Coronary Computed Tomography Angiography) diagnostic pathway to evaluate and manage CAD.

FISH&CHIPS two-year key outcomes associated with availability of FFR_CT include:

• A significant 14% relative reduction in cardiovascular mortality and a significant 8% relative reduction in all-cause mortality.
• An increase in cath lab efficiency, driven by a 5% relative reduction in invasive cardiac angiography (ICA) and an 8% relative increase in Percutaneous Coronary Intervention (PCI).
• A 14% relative reduction in additional non-invasive heart testing following CCTA.
• High prognostic value for FFR_CT whereby patients with severely abnormal FFR_CT values (≤0.50) had a 2x risk of all-cause death and a 3x risk of non-fatal MI compared to patients with normal FFR_CT values.

Click the button below to read the entire Press Release:

Continue Reading The Press Release